Literature DB >> 35287165

Metabolome-Defined Obesity and the Risk of Future Type 2 Diabetes and Mortality.

Filip Ottosson1,2, Einar Smith1, Ulrika Ericson1, Louise Brunkwall1, Marju Orho-Melander1, Salvatore Di Somma3,4, Paola Antonini4, Peter M Nilsson1, Céline Fernandez1, Olle Melander1.   

Abstract

OBJECTIVE: Obesity is a key risk factor for type 2 diabetes; however, up to 20% of patients are normal weight. Our aim was to identify metabolite patterns reproducibly predictive of BMI and subsequently to test whether lean individuals who carry an obese metabolome are at hidden high risk of obesity-related diseases, such as type 2 diabetes. RESEARCH DESIGN AND METHODS: Levels of 108 metabolites were measured in plasma samples of 7,663 individuals from two Swedish and one Italian population-based cohort. Ridge regression was used to predict BMI using the metabolites. Individuals with a predicted BMI either >5 kg/m2 higher (overestimated) or lower (underestimated) than their actual BMI were characterized as outliers and further investigated for obesity-related risk factors and future risk of type 2 diabetes and mortality.
RESULTS: The metabolome could predict BMI in all cohorts (r2 = 0.48, 0.26, and 0.19). The overestimated group had a BMI similar to individuals correctly predicted as normal weight, had a similar waist circumference, were not more likely to change weight over time, but had a two times higher risk of future type 2 diabetes and an 80% increased risk of all-cause mortality. These associations remained after adjustments for obesity-related risk factors and lifestyle parameters.
CONCLUSIONS: We found that lean individuals with an obesity-related metabolome have an increased risk for type 2 diabetes and all-cause mortality compared with lean individuals with a healthy metabolome. Metabolomics may be used to identify hidden high-risk individuals to initiate lifestyle and pharmacological interventions.
© 2022 by the American Diabetes Association.

Entities:  

Mesh:

Year:  2022        PMID: 35287165      PMCID: PMC9174969          DOI: 10.2337/dc21-2402

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   17.152


  22 in total

1.  Incident coronary events and case fatality in relation to common carotid intima-media thickness.

Authors:  M Rosvall; L Janzon; G Berglund; G Engström; B Hedblad
Journal:  J Intern Med       Date:  2005-05       Impact factor: 8.989

2.  Altered Asparagine and Glutamate Homeostasis Precede Coronary Artery Disease and Type 2 Diabetes.

Authors:  Filip Ottosson; Einar Smith; Olle Melander; Céline Fernandez
Journal:  J Clin Endocrinol Metab       Date:  2018-08-01       Impact factor: 5.958

3.  Plasma Lipidome and Prediction of Type 2 Diabetes in the Population-Based Malmö Diet and Cancer Cohort.

Authors:  Céline Fernandez; Michal A Surma; Christian Klose; Mathias J Gerl; Filip Ottosson; Ulrika Ericson; Nikolay Oskolkov; Marju Ohro-Melander; Kai Simons; Olle Melander
Journal:  Diabetes Care       Date:  2019-12-08       Impact factor: 19.112

Review 4.  Metabolically healthy obesity: definitions, determinants and clinical implications.

Authors:  Catherine M Phillips
Journal:  Rev Endocr Metab Disord       Date:  2013-09       Impact factor: 6.514

5.  Metabolically healthy obesity (MHO) in the Malmö diet cancer study - Epidemiology and prospective risks.

Authors:  Johan Korduner; Erasmus Bachus; Amra Jujic; Martin Magnusson; Peter M Nilsson
Journal:  Obes Res Clin Pract       Date:  2019-11-08       Impact factor: 2.288

6.  Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts.

Authors:  Peter Würtz; Aki S Havulinna; Pasi Soininen; Tuulia Tynkkynen; David Prieto-Merino; Therese Tillin; Anahita Ghorbani; Anna Artati; Qin Wang; Mika Tiainen; Antti J Kangas; Johannes Kettunen; Jari Kaikkonen; Vera Mikkilä; Antti Jula; Mika Kähönen; Terho Lehtimäki; Debbie A Lawlor; Tom R Gaunt; Alun D Hughes; Naveed Sattar; Thomas Illig; Jerzy Adamski; Thomas J Wang; Markus Perola; Samuli Ripatti; Ramachandran S Vasan; Olli T Raitakari; Robert E Gerszten; Juan-Pablo Casas; Nish Chaturvedi; Mika Ala-Korpela; Veikko Salomaa
Journal:  Circulation       Date:  2015-01-08       Impact factor: 29.690

7.  Metabolites of Glutamate Metabolism Are Associated With Incident Cardiovascular Events in the PREDIMED PREvención con DIeta MEDiterránea (PREDIMED) Trial.

Authors:  Yan Zheng; Frank B Hu; Miguel Ruiz-Canela; Clary B Clish; Courtney Dennis; Jordi Salas-Salvado; Adela Hruby; Liming Liang; Estefania Toledo; Dolores Corella; Emilio Ros; Montserrat Fitó; Enrique Gómez-Gracia; Fernando Arós; Miquel Fiol; José Lapetra; Lluis Serra-Majem; Ramón Estruch; Miguel A Martínez-González
Journal:  J Am Heart Assoc       Date:  2016-09-15       Impact factor: 5.501

8.  Purine Metabolites and Carnitine Biosynthesis Intermediates Are Biomarkers for Incident Type 2 Diabetes.

Authors:  Filip Ottosson; Einar Smith; Widet Gallo; Céline Fernandez; Olle Melander
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

9.  The Malmö Offspring Study (MOS): design, methods and first results.

Authors:  Louise Brunkwall; Daniel Jönsson; Ulrika Ericson; Sophie Hellstrand; Cecilia Kennbäck; Gerd Östling; Amra Jujic; Olle Melander; Gunnar Engström; Jan Nilsson; Bodil Ohlsson; Björn Klinge; Marju Orho-Melander; Margaretha Persson; Peter M Nilsson
Journal:  Eur J Epidemiol       Date:  2020-11-21       Impact factor: 8.082

10.  Comparison of cardiovascular disease and cancer prevalence between Mediterranean and north European middle-aged populations (The Cilento on Ageing Outcomes Study and The Malmö Offspring Study).

Authors:  Olle Melander; Paola Antonini; Filip Ottosson; Louise Brunkwall; Widet Gallo; Peter M Nilsson; Marju Orho-Melander; Gaetano Pacente; Giovanni D'Arena; Salvatore Di Somma
Journal:  Intern Emerg Med       Date:  2021-01-30       Impact factor: 3.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.